Compounds > edaravone
Page last updated: 2024-10-30

edaravone and Brain Ischemia

edaravone has been researched along with Brain Ischemia in 108 studies

Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI)."9.51The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. ( Shen, QQ; Tong, XW; Wang, W; Wu, H, 2022)
" Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined."9.41Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. ( Li, LD; Shi, SF; Zhou, Y, 2023)
" Here we analyzed the clinical outcomes of acute ischemic stroke (AIS) patients treated with human urinary kallidinogenase (HUK) or edaravone (Eda) combined with butylphthalide (NBP)."9.30Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke. ( Jiang, M; Lu, S; Lyu, Y; Nie, T; Qian, Y; Tang, B, 2019)
"To test the hypothesis that edaravone reduces functional dependence in ischemic stroke patients."9.22Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022)
"All patients of age more than 18 years who presented within 24 hours of acute ischemic stroke were randomly treated with Edaravone (group E), Citicoline (group C) or none (group N) with other standard treatment of AIS."9.16Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012)
"Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients."9.14Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010)
"Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients."9.12Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. ( Chen, LQ; Guan, B; Li, Y; Ming, Q; Yang, DX; Yu, D, 2021)
"To assess the efficacy and safety of edaravone for acute ischaemic stroke."8.87Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011)
"Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually."8.86A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010)
"DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment."8.31A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023)
" Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired."8.31Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury. ( Fukuta, T; Ikeda-Imafuku, M; Iwao, Y, 2023)
" Hydroxysafflor Yellow A (HSYA), a popular herbal medicine, is an extract of Carthamus tinctorius and is used to treat ischemic stroke (IS) in China."8.12Hydroxysafflor Yellow A Alleviates Ischemic Stroke in Rats via HIF-1[Formula: see text], BNIP3, and Notch1-Mediated Inhibition of Autophagy. ( Cui, Q; Fu, Z; Ge, S; Liu, A; Liu, J; Liu, Y; Qin, X; Yu, H; Zhang, G; Zhang, Y, 2022)
"The neuroprotection of acute cerebral infarction (ACI) model by edaravone dexborneol (ED)-mediated Keap1-Nrf2/ARE signal pathway was investigated."8.12Keap1-Nrf2/ARE Pathway-based Investigation into the Mechanism of Edaravone Dexborneol in Cerebral Infarction Model Neuroprotection. ( Wang, B; Wang, Y; Yang, X, 2022)
"Mild hypothermia (MH) and edaravone (EDA) exert neuroprotective effects against cerebral ischemia/reperfusion (I/R) injury through activation of the nuclear factor erythroid 2‑related factor 2 (Nrf2) pathway."7.96Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation. ( Dai, M; Gao, C; Kang, F; Liu, R; Wang, X; Wu, Z; Yu, H, 2020)
"Background and Purpose- Although several clinical studies suggested the beneficial effects of edaravone in acute ischemic stroke, most were performed under settings that differ from those in the current treatment strategy, which has dramatically changed with progress in reperfusion therapies."7.91Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. ( Endo, A; Enomoto, M; Fushimi, K; Otomo, Y; Yatsushige, H, 2019)
"Background and Purpose- In Japan, nearly half of ischemic stroke patients receive edaravone for acute treatment."7.91Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. ( Fukuhara, S; Fukuma, S; Ikenoue, T; Kobayashi, S, 2019)
"Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2."7.88Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018)
"Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome."7.88Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. ( Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T, 2018)
"Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset."7.85Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017)
"To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms."7.81[Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury 
in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015)
"One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone."7.79Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013)
"Although AKI has a significant impact on the clinical outcome of hospital inpatients, edaravone has a protective effect against the development of AKI in patients with acute ischemic stroke."7.79Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013)
"To compare the protective effect of nerve growth factor (NGF) and edaravone (a free radical scavenger) pretreatment against cerebral ischemia/reperfusion (I/R) injury to nerve cells."7.76[A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury]. ( Fu, JQ; Liu, H; Wang, DF, 2010)
" Edaravone, a free radical scavenger, has neuroprotective effects against focal cerebral ischemia even in humans."7.75Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. ( Inada, T; Jomura, S; Kubo, K; Miyamoto, E; Nakao, S; Sakamoto, S; Shingu, K; Tomimoto, H; Xu, Y, 2009)
"We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil."7.71Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002)
"Edaravone has been used in patients with acute ischemic stroke in Japan for over 10 years but does not have marketing authorization in Europe or America."6.50Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. ( Egan, K; Macleod, M; Mead, G; Sena, E; Wu, S, 2014)
"Edaravone dexborneol is a novel neuroprotective agent consisting of edaravone and borneol."5.72Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice. ( Dong, Y; Gao, Y; Hu, M; Lv, P; Xu, J; Xu, L; Zhang, J, 2022)
" Although EDV promotes ischemic recovery by inhibiting the generation of ROS, its poor safety and bioavailability limit its clinical applications."5.62A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. ( Guo, L; Li, F; Pan, J; Shi, Y; Zhao, L, 2021)
"Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion."5.56Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2020)
" Here, we developed macrophage-derived exosomes (Exo) containing Edv (Exo + Edv) to improve the bioavailability of Edv and enhance the neuroprotective effects in a rat model of permanent middle cerebral artery occlusion (PMCAO)."5.56Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020)
"This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI)."5.51The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. ( Shen, QQ; Tong, XW; Wang, W; Wu, H, 2022)
" Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined."5.41Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. ( Li, LD; Shi, SF; Zhou, Y, 2023)
"Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect."5.40The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014)
" No adverse events were observed."5.38Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012)
"Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls."5.33Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005)
" Here we analyzed the clinical outcomes of acute ischemic stroke (AIS) patients treated with human urinary kallidinogenase (HUK) or edaravone (Eda) combined with butylphthalide (NBP)."5.30Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke. ( Jiang, M; Lu, S; Lyu, Y; Nie, T; Qian, Y; Tang, B, 2019)
"To test the hypothesis that edaravone reduces functional dependence in ischemic stroke patients."5.22Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022)
"To identify prognostic factors affecting outcomes at 90 days after stroke from the viewpoint of recovery patterns, we enrolled 660 patients from the Edaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke study database."5.17Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset. ( Kumagai, N; Nagao, T; Okuhara, Y; Origasa, H; Takekawa, H; Yamaguchi, T, 2013)
"All patients of age more than 18 years who presented within 24 hours of acute ischemic stroke were randomly treated with Edaravone (group E), Citicoline (group C) or none (group N) with other standard treatment of AIS."5.16Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012)
"Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients."5.14Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010)
"Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients."5.12Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis. ( Chen, LQ; Guan, B; Li, Y; Ming, Q; Yang, DX; Yu, D, 2021)
"To assess the efficacy and safety of edaravone for acute ischaemic stroke."4.87Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011)
"Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually."4.86A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010)
" Four compounds with free radical scavenging activity (tirilazad, ebselen, edaravone) or free radical trapping properties (NXY-059) have been examined in experimental models of stroke and evaluated clinically as neuroprotective agents."4.82Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. ( Ashwood, T; Green, AR, 2005)
" Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired."4.31Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury. ( Fukuta, T; Ikeda-Imafuku, M; Iwao, Y, 2023)
"DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment."4.31A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
" Hydroxysafflor Yellow A (HSYA), a popular herbal medicine, is an extract of Carthamus tinctorius and is used to treat ischemic stroke (IS) in China."4.12Hydroxysafflor Yellow A Alleviates Ischemic Stroke in Rats via HIF-1[Formula: see text], BNIP3, and Notch1-Mediated Inhibition of Autophagy. ( Cui, Q; Fu, Z; Ge, S; Liu, A; Liu, J; Liu, Y; Qin, X; Yu, H; Zhang, G; Zhang, Y, 2022)
"The neuroprotection of acute cerebral infarction (ACI) model by edaravone dexborneol (ED)-mediated Keap1-Nrf2/ARE signal pathway was investigated."4.12Keap1-Nrf2/ARE Pathway-based Investigation into the Mechanism of Edaravone Dexborneol in Cerebral Infarction Model Neuroprotection. ( Wang, B; Wang, Y; Yang, X, 2022)
"DL‑3‑n‑butylphthalide (NBP) and 3‑methyl‑1- phenyl‑2‑pyrazolin‑5‑one (edaravone) are acknowledged neuroprotective agents that protect against ischemic stroke."4.02Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke. ( Cheng, Y; Guan, Y; Guo, L; Li, P; Liu, Y; Wu, Q, 2021)
"Mild hypothermia (MH) and edaravone (EDA) exert neuroprotective effects against cerebral ischemia/reperfusion (I/R) injury through activation of the nuclear factor erythroid 2‑related factor 2 (Nrf2) pathway."3.96Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation. ( Dai, M; Gao, C; Kang, F; Liu, R; Wang, X; Wu, Z; Yu, H, 2020)
"Background and Purpose- Although several clinical studies suggested the beneficial effects of edaravone in acute ischemic stroke, most were performed under settings that differ from those in the current treatment strategy, which has dramatically changed with progress in reperfusion therapies."3.91Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. ( Endo, A; Enomoto, M; Fushimi, K; Otomo, Y; Yatsushige, H, 2019)
"Background and Purpose- In Japan, nearly half of ischemic stroke patients receive edaravone for acute treatment."3.91Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke. ( Fukuhara, S; Fukuma, S; Ikenoue, T; Kobayashi, S, 2019)
"Uric acid (UA), an antioxidant with neuroprotective effects, favorably affects stroke outcome."3.88Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone. ( Ando, Y; Inatomi, Y; Naganuma, M; Nakajima, M; Yonehara, T, 2018)
"Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2."3.88Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018)
"Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset."3.85Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017)
"Seventeen pediatric patients with cerebral ischemia were administered edaravone at a dose based on body weight from the standard dose given to adults."3.81Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone. ( Aihara, Y; Kawamata, T; Nakamoto, H; Okada, Y; Yamaguchi, K, 2015)
"Compound IMM-H004 (7-hydroxy-5-methoxy-4-methyl-3-[4-methylpiperazin-1-yl]-2H-chromen-2-one) is a new synthetic derivative of coumarin, and previous studies showed that it exhibited antioxidant and neuroprotective roles in focal cerebral ischemia."3.81Compound IMM-H004, a novel coumarin derivative, protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia. ( Chen, NH; Han, N; Zhang, W; Zuo, W, 2015)
"To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms."3.81[Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury 
in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015)
"One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone."3.79Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013)
"Although AKI has a significant impact on the clinical outcome of hospital inpatients, edaravone has a protective effect against the development of AKI in patients with acute ischemic stroke."3.79Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013)
"To compare the protective effect of nerve growth factor (NGF) and edaravone (a free radical scavenger) pretreatment against cerebral ischemia/reperfusion (I/R) injury to nerve cells."3.76[A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury]. ( Fu, JQ; Liu, H; Wang, DF, 2010)
"Edaravone, a drug for treating acute ischemic stroke, has been reported to provoke acute renal disorders."3.75Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. ( Hishida, A, 2009)
"We demonstrate that edaravone inhibits rtPA-induced cerebral hemorrhage in the ischemic brain of rats via the inhibition of MMP-9 expression in vivo, which is substantiated by inhibition of MMP-9 expression and NF-kappaB activation in HBECs."3.75Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. ( Kinouchi, T; Kitazato, KT; Nagahiro, S; Shimada, K; Tada, Y; Uno, M; Yagi, K, 2009)
" Edaravone, a free radical scavenger, has neuroprotective effects against focal cerebral ischemia even in humans."3.75Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. ( Inada, T; Jomura, S; Kubo, K; Miyamoto, E; Nakao, S; Sakamoto, S; Shingu, K; Tomimoto, H; Xu, Y, 2009)
"We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil."3.71Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002)
"Edaravone has been used in patients with acute ischemic stroke in Japan for over 10 years but does not have marketing authorization in Europe or America."2.50Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. ( Egan, K; Macleod, M; Mead, G; Sena, E; Wu, S, 2014)
"Edaravone dexborneol is a novel neuroprotective agent consisting of edaravone and borneol."1.72Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice. ( Dong, Y; Gao, Y; Hu, M; Lv, P; Xu, J; Xu, L; Zhang, J, 2022)
" Although EDV promotes ischemic recovery by inhibiting the generation of ROS, its poor safety and bioavailability limit its clinical applications."1.62A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke. ( Guo, L; Li, F; Pan, J; Shi, Y; Zhao, L, 2021)
" The present study demonstrates that the long-term administration of EDA may provide a promising therapeutic approach for WMLs in AD plus CCH disease with cognitive deficits."1.62Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion. ( Abe, K; Feng, T; Hishikawa, N; Matsumoto, N; Sasaki, R; Tadokoro, K; Yamashita, T, 2021)
"Edaravone (3 mg/kg) was administered intravenously to 14 C57BL/6 mice just before reperfusion."1.56Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2020)
" Here, we developed macrophage-derived exosomes (Exo) containing Edv (Exo + Edv) to improve the bioavailability of Edv and enhance the neuroprotective effects in a rat model of permanent middle cerebral artery occlusion (PMCAO)."1.56Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020)
"Rat transient middle cerebral artery occlusion (MCAO) model was established."1.43Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016)
"In response to cerebral ischemia, activated microglia release excessive inflammatory mediators which contribute to neuronal damage."1.40Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. ( Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014)
"Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect."1.40The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014)
" No adverse events were observed."1.38Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012)
"Edaravone treatment significantly reduced the lesion volume and improved the neurological score."1.35Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model. ( Fujii, M; Fujisawa, H; Gondo, T; Izuma, H; Kajiwara, K; Kato, S; Nomura, S; Oka, F; Suzuki, M; Uozumi, K, 2009)
"Treatment with serofendic acid (1-30 nmol) reduced the infarct volume in a dose-dependent manner."1.35Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats. ( Akaike, A; Katsuki, H; Kume, T; Nakamura, T; Niidome, T; Sugimoto, H, 2008)
"In in vitro models of cerebral ischemia, exposure to hydrogen peroxide or glutamate induced cell death with overactivation of PARP, and treatment with DR2313 reduced excessive formation of poly(ADP-ribose) and cell death."1.33A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. ( Hasegawa, T; Ishikawa, M; Kakui, N; Nakajima, H; Ohkuma, K, 2005)
"Edaravone-treated animals showed significantly improved neurological outcome."1.33Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. ( Amemiya, S; Inaba, T; Kamiya, T; Katayama, Y; Kato, K; Nito, C; Shimazaki, K; Ueda, M, 2005)
"Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion."1.33Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005)
"Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls."1.33Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005)
"Edaravone and ONO-1078 were added into the incubation medium to observe their neuroprotective effects."1.32[An improved quantitative method for evaluation of ischemic injury and neuroprotection in mouse brain slices]. ( Ge, QF; Peng, GP; Wei, EQ; Yu, LF, 2003)
"Edaravone+tPA-treated group: Edaravone (3 mg/kg, i."1.32Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. ( Abe, K; Hayashi, T; Horiuchi, S; Kato, S; Nagano, I; Omori, N; Sato, K; Zhang, W, 2004)
"Metabolic disruption resulted from cerebral ischemia and post-ischemia reperfusion injury was studied using proton magnetic resonance spectroscopy (1H MRS)."1.30[In vitro evaluation of metabolic change in forebrain ischemia model of rat using proton magnetic resonance spectroscopy]. ( Tanaka, N, 1997)

Research

Studies (108)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.93)18.7374
1990's5 (4.63)18.2507
2000's35 (32.41)29.6817
2010's42 (38.89)24.3611
2020's25 (23.15)2.80

Authors

AuthorsStudies
Sun, Y3
Jiang, J1
Zhang, Z1
Yu, P1
Wang, L6
Xu, C1
Liu, W5
Wang, Y6
Wu, J2
Ling, J1
Wang, X6
Li, T3
Liu, J4
Lai, Y1
Ji, H1
Peng, S2
Tian, J1
Zhang, Y8
Sun, M2
Hu, J1
Song, X4
Wu, D1
Kong, L2
Wang, D2
Chen, N2
Liu, G1
Huang, L2
Wang, J7
Chen, L2
Zhu, M1
Wu, S4
Chu, S2
Zheng, Y1
Fan, Z1
Zhang, J5
Li, W4
Chen, D1
Yang, X3
Wang, S2
Qiu, P1
Zang, Y1
Li, C4
Ma, J2
Liu, D2
Ren, Q1
Li, Y9
Zhang, D2
Marco-Contelles, J1
Wang, H4
Cui, E1
Li, J3
Ma, X1
Jiang, X1
Du, S1
Qian, S1
Du, L1
Guan, Y1
Li, P2
Liu, Y5
Guo, L2
Wu, Q1
Cheng, Y1
Pan, J1
Li, F2
Zhao, L2
Shi, Y2
Yang, DX1
Yu, D1
Guan, B1
Ming, Q1
Chen, LQ1
Cui, Q1
Fu, Z1
Yu, H2
Liu, A1
Qin, X1
Ge, S1
Zhang, G2
Xu, L1
Gao, Y2
Hu, M1
Dong, Y3
Xu, J1
Lv, P2
Fidalgo, M1
Ricardo Pires, J1
Viseu, I1
Magalhães, P1
Gregório, H1
Afreixo, V1
Gregório, T1
Huang, Y2
Zhang, X3
Zhang, C1
Xu, W1
Feng, Z2
Zhao, K1
Liu, C4
Dai, Z1
Tang, B2
Shen, QQ1
Wang, W1
Wu, H1
Tong, XW1
Li, LD1
Zhou, Y2
Shi, SF1
Wang, B1
Fukuta, T1
Ikeda-Imafuku, M1
Iwao, Y1
Zhang, H2
Zhu, B1
Yang, Y4
Cai, C2
Deng, L2
He, B1
Cui, Y1
Zhou, W2
Feng, T2
Yamashita, T7
Shang, J3
Shi, X2
Nakano, Y2
Morihara, R1
Tsunoda, K2
Nomura, E2
Sasaki, R3
Tadokoro, K3
Matsumoto, N2
Hishikawa, N3
Ohta, Y3
Abe, K8
Tian, F3
Li, X6
Liu, X2
Sato, K2
Takemoto, M1
Qian, Y1
Lyu, Y1
Jiang, M1
Nie, T1
Lu, S1
Kawasaki, H1
Ito, Y1
Kitabayashi, C1
Tanaka, A1
Nishioka, R1
Yamazato, M1
Ishizawa, K1
Nagai, T1
Hirayama, M1
Takahashi, K1
Yamamoto, T2
Araki, N1
Wu, Z1
Gao, C1
Liu, R1
Kang, F1
Dai, M1
Liang, J1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Xu, T1
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J1
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X2
Chen, Y5
Wei, J1
Zhu, C1
Wu, C2
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Lin, Y1
Wu, Y1
Bao, Y1
Yan, H2
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J3
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H2
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X1
Xu, S2
Lu, C3
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J2
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X3
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Yu, X1
Feng, B1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Zhang, Q2
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H5
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M4
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B2
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z3
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y2
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q2
Lin, CC1
Hsu, CT1
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L2
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Qian, H1
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Yang, W1
Miao, L1
Guo, Y1
Yuan, R1
Tian, H1
Vdovychenko, YP1
Loskutov, OA1
Halushko, OA1
Trishchynska, MA1
Dziuba, DO1
Povietkina, TM1
Vitiuk, AD1
Matsumoto, M2
Miyamoto, M1
Sawahata, M1
Izumi, Y1
Takada-Takatori, Y1
Kume, T2
Jin, Q1
Cai, Y1
Li, S1
Zhou, X1
Qian, J1
Ju, S1
Xiao, Y2
Teng, Z1
Qi, Q1
Liu, Z1
Takase, H1
Liang, AC1
Miyamoto, N3
Hamanaka, G1
Ohtomo, R1
Maki, T2
Pham, LD2
Lok, J1
Lo, EH2
Arai, K2
Tanahashi, N4
Yamaguchi, T4
Awano, H2
Matsuda, H2
Lee, XR1
Xiang, GL1
Song, Y1
Bei, Y1
Tong, HD1
Wu, XQ1
Chen, MT1
Naganuma, M1
Inatomi, Y2
Nakajima, M1
Yonehara, T2
Ando, Y1
Enomoto, M1
Endo, A1
Yatsushige, H1
Fushimi, K1
Otomo, Y1
Kobayashi, S2
Fukuma, S1
Ikenoue, T2
Fukuhara, S1
Meng, W1
Lu, L1
Wei, Y1
Peng, X1
Yang, A1
He, Y1
Dong, L1
Kono, S2
Deguchi, K4
Morimoto, N1
Kurata, T1
Ikeda, Y2
Narai, H1
Manabe, Y1
Takao, Y1
Kawada, S1
Kashihara, K1
Takehisa, Y1
Inoue, S1
Kiriyama, H1
Wang, G1
Su, J1
Shi, L1
He, W1
Wu, CY1
Zha, H2
Xia, QQ1
Yuan, Y2
Liang, XY1
Li, JH1
Guo, ZY1
Li, JJ1
Mitta, M1
Goel, D1
Bansal, KK1
Puri, P1
Kamouchi, M1
Sakai, H1
Kiyohara, Y1
Minematsu, K1
Hayashi, K1
Kitazono, T1
Omote, Y2
Kawai, H2
Hayakawa, K1
Seo, JH1
Mandeville, ET1
Mandeville, JB1
Kim, KW1
Sena, E1
Egan, K1
Macleod, M1
Mead, G1
Liu, N1
Yunoki, T1
Deguchi, S1
Wu, HY1
Tang, Y1
Gao, LY1
Sun, WX1
Hua, Y1
Yang, SB1
Zhang, ZP1
Liao, GY1
Zhou, QG1
Luo, CX1
Zhu, DY1
Ren, Y1
Wei, B1
An, N1
Jin, X1
Rangarajan, P1
Ling, EA1
Zuo, W1
Zhang, W2
Han, N1
Chen, NH1
Zhang, S2
Hou, S1
Chen, H1
Nakamoto, H1
Aihara, Y1
Yamaguchi, K1
Kawamata, T1
Okada, Y1
Shen, LH1
Shen, HC1
Ye, M1
Liu, XF1
Ding, WS1
Sheng, YF1
Ding, XS1
Wang, DF3
Fu, JQ2
Hishida, A1
Yagi, K1
Kitazato, KT1
Uno, M1
Tada, Y1
Kinouchi, T1
Shimada, K1
Nagahiro, S1
Kamiya, T2
Inaba, T2
Miyazaki, K1
Ohtsuka, A1
Katayama, Y4
Oka, F1
Fujisawa, H1
Nomura, S1
Kajiwara, K1
Kato, S2
Fujii, M1
Izuma, H1
Uozumi, K1
Gondo, T1
Suzuki, M1
Ueno, Y1
Zhang, N2
Tanaka, R2
Hattori, N1
Urabe, T2
Kubo, K1
Nakao, S1
Jomura, S1
Sakamoto, S1
Miyamoto, E1
Tomimoto, H1
Inada, T1
Shingu, K1
Kikuchi, K2
Tancharoen, S1
Matsuda, F1
Biswas, KK1
Ito, T1
Morimoto, Y1
Oyama, Y1
Takenouchi, K1
Miura, N1
Arimura, N1
Nawa, Y1
Meng, X1
Shrestha, B1
Arimura, S1
Iwata, M1
Mera, K1
Sameshima, H1
Ohno, Y1
Maenosono, R1
Tajima, Y1
Uchikado, H1
Kuramoto, T1
Nakayama, K1
Shigemori, M1
Yoshida, Y1
Hashiguchi, T1
Maruyama, I1
Kawahara, K1
Yamamoto, Y2
Yanagisawa, M1
Tak, NW1
Watanabe, K3
Takahashi, C1
Fujisawa, A1
Kashiba, M1
Tanaka, M2
Richard, MJ1
Saleh, TM1
El Bahh, B1
Zidichouski, JA1
Lapchak, PA1
Naritomi, H1
Moriwaki, H1
Metoki, N1
Nishimura, H1
Higashi, Y1
Yuasa, H1
Oe, H1
Tanaka, K1
Saito, K1
Terayama, Y1
Oda, T1
Kondo, H1
Jiao, L1
Baba, H1
Sugimori, H1
Nanishi, E1
Nagata, H1
Lee, S1
Kuwashiro, T1
Hashizume, M1
Feng, S1
Yuan, W1
Yao, N1
Liu, XL1
Kumagai, N1
Origasa, H1
Nagao, T1
Takekawa, H1
Okuhara, Y1
Ge, QF1
Wei, EQ3
Peng, GP1
Yu, LF1
Watanabe, T5
Takamatsu, Y1
Tobe, A1
Wang, ML1
Liu, LY1
Hayashi, T1
Omori, N1
Nagano, I1
Horiuchi, S1
Igarashi, H2
Qi, X1
Okuma, Y1
Hosoi, T1
Nomura, Y1
Yu, GL1
Zhang, SH1
Xu, HM1
Chu, LS1
Zhang, WP1
Chen, Z1
Mei, RH1
Zhao, MH1
Nakajima, H1
Kakui, N1
Ohkuma, K1
Ishikawa, M1
Hasegawa, T1
Shichinohe, H1
Kuroda, S1
Yasuda, H1
Ishikawa, T1
Iwai, M1
Horiuchi, M1
Iwasaki, Y1
Otani, H1
Togashi, H1
Jesmin, S1
Sakuma, I1
Kakehata, H1
Yoshioka, M1
Green, AR1
Ashwood, T1
Amemiya, S1
Nito, C1
Kato, K1
Ueda, M1
Shimazaki, K1
Yokota, A1
Nakai, A1
Taniuchi, Y1
Okuda, N1
Nakai, M1
Takeshita, T1
Lee, JH1
Park, SY1
Lee, WS1
Hong, KW1
Komine-Kobayashi, M1
Mizuno, Y1
Noor, JI1
Ikeda, T1
Mishima, K1
Aoo, N1
Ohta, S1
Egashira, N1
Iwasaki, K1
Fujiwara, M1
Aizawa, H1
Makita, Y1
Sumitomo, K1
Aburakawa, Y1
Katayama, T1
Nakatani-Enomoto, S1
Suzuki, Y1
Fujiwara, K1
Enomoto, H1
Kuroda, K1
Kimura, T1
Yahara, O1
Koyama, S1
Maruyama, J1
Nakamura, M1
Hasebe, N1
Itoh, Y2
Takaoka, R1
Ohira, M1
Abe, T1
Suzuki, N1
Kitagawa, Y1
Takita, T1
Fujioka, S1
Hashimoto, Y1
Hirano, T1
Uchino, M1
Ma, M1
Wen, J1
Kodama, M1
Aizawa, Y1
Suda, S1
Arai, Y1
Andou, J1
Chishiki, T1
Takizawa, S1
Izuhara, Y1
Kitao, Y1
Hori, O1
Ogawa, S1
Morita, Y1
Takagi, S1
van Ypersele de Strihou, C1
Miyata, T1
Nakamura, T1
Katsuki, H1
Niidome, T1
Sugimoto, H1
Akaike, A1
Yuki, S3
Egawa, M1
Nishi, H2
Nakai, H1
Suga, M1
Saito, KI2
Tanaka, N1
Mitsuka, M1
Kogure, K1
Mizuno, A1
Umemura, K1
Nakashima, M1
Jin, YJ1
Mima, T1
Raicu, V1
Park, KC1
Shimizu, K1
Oishi, R1
Nishibori, M1
Saeki, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy[NCT00153946]Phase 4814 participants (Actual)Interventional2004-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

11 reviews available for edaravone and Brain Ischemia

ArticleYear
Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta-analysis.
    Brain and behavior, 2021, Volume: 11, Issue:12

    Topics: Brain Ischemia; Edaravone; Humans; Ischemic Stroke; Stroke; Tissue Kallikreins; Treatment Outcome

2021
Edaravone for acute ischemic stroke - Systematic review with meta-analysis.
    Clinical neurology and neurosurgery, 2022, Volume: 219

    Topics: Adult; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Intracranial Hemorrha

2022
Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis.
    Medicine, 2023, Mar-03, Volume: 102, Issue:9

    Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Edaravone; Humans; Stroke

2023
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:1

    Topics: Animals; Antipyrine; Brain; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavenge

2014
Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature.
    The International journal of neuroscience, 2015, Volume: 125, Issue:8

    Topics: Animals; Antipyrine; Brain Ischemia; Databases, Bibliographic; Edaravone; Free Radical Scavengers; H

2015
A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10

    Topics: Animals; Antipyrine; Brain Ischemia; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavenger

2010
Edaravone for acute ischaemic stroke.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Rand

2011
[Research and development of the free radical scavenger edaravone as a neuroprotectant].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2004, Volume: 124, Issue:3

    Topics: Animals; Antipyrine; Brain Ischemia; Clinical Trials as Topic; Drug Design; Edaravone; Edema; Free R

2004
[Advances in the diagnosis and treatment of cerebral ischemia during the acute phase].
    Rinsho shinkeigaku = Clinical neurology, 2003, Volume: 43, Issue:11

    Topics: Acute-Phase Reaction; Antipyrine; Brain Ischemia; Cerebrovascular Circulation; Drug Design; Drug The

2003
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
    Current drug targets. CNS and neurological disorders, 2005, Volume: 4, Issue:2

    Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radica

2005

Trials

6 trials available for edaravone and Brain Ischemia

ArticleYear
The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2022, Volume: 73, Issue:3

    Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Edaravone; Humans; Interleukin-10; Phosphopyruva

2022
Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke.
    Brain and behavior, 2019, Volume: 9, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Benzofurans; Brain Ischemia; Drug Therapy, Combination; Edaravone; F

2019
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS).
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipyrine; Brain Ischemia; Cytidi

2012
Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study.
    Drugs in R&D, 2010, Volume: 10, Issue:3

    Topics: Aged; Antipyrine; Brain Ischemia; Drug Administration Schedule; Edaravone; Female; Free Radical Scav

2010
Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6

    Topics: Aged; Aged, 80 and over; Antipyrine; Arginine; Brain Ischemia; Chi-Square Distribution; Disability E

2013

Other Studies

92 other studies available for edaravone and Brain Ischemia

ArticleYear
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
    Bioorganic & medicinal chemistry, 2008, Oct-01, Volume: 16, Issue:19

    Topics: Animals; Antioxidants; Brain Ischemia; Fibrinolytic Agents; Nitrogen Oxides; Pyrazines; Rats; Stroke

2008
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
    Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16

    Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Fr

2012
Coumarin derivatives protect against ischemic brain injury in rats.
    European journal of medicinal chemistry, 2013, Volume: 67

    Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Coumarins; Male; Molecular Structure; Neuroprotective

2013
Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents.
    European journal of medicinal chemistry, 2018, Jan-01, Volume: 143

    Topics: Animals; Brain Ischemia; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Hydrogen Pero

2018
Pyrano[3,2-a]carbazole alkaloids as effective agents against ischemic stroke in vitro and in vivo.
    European journal of medicinal chemistry, 2018, Jan-01, Volume: 143

    Topics: Alkaloids; Animals; Blood-Brain Barrier; Brain Ischemia; Carbazoles; Cell Survival; Cells, Cultured;

2018
From Seeds of
    Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21

    Topics: Animals; Apium; Asthma; Benzofurans; Brain Ischemia; Humans; Neuroprotective Agents; Seeds; Stereois

2020
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
    European journal of medicinal chemistry, 2022, Nov-05, Volume: 241

    Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol

2022
Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke.
    Molecular medicine reports, 2021, Volume: 24, Issue:6

    Topics: Animals; Apoptosis Regulatory Proteins; Benzofurans; Brain Ischemia; Disease Models, Animal; Drug Th

2021
A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke.
    IET nanobiotechnology, 2021, Volume: 15, Issue:1

    Topics: Brain; Brain Ischemia; Edaravone; Exosomes; Free Radical Scavengers; Humans; Ischemic Stroke; Stroke

2021
Hydroxysafflor Yellow A Alleviates Ischemic Stroke in Rats via HIF-1[Formula: see text], BNIP3, and Notch1-Mediated Inhibition of Autophagy.
    The American journal of Chinese medicine, 2022, Volume: 50, Issue:3

    Topics: Animals; Autophagy; Brain Ischemia; Chalcone; Edaravone; Hypoxia-Inducible Factor 1; Ischemic Stroke

2022
Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice.
    Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:5

    Topics: Animals; Antioxidants; Apoptosis; Brain Ischemia; Edaravone; Heme Oxygenase-1; Inflammation; Membran

2022
Edaravone Dexborneol Downregulates Neutrophil Extracellular Trap Expression and Ameliorates Blood-Brain Barrier Permeability in Acute Ischemic Stroke.
    Mediators of inflammation, 2022, Volume: 2022

    Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Deoxyribonuclease I; Edaravone; Extracellular Traps; H

2022
Edaravone Ameliorates Cerebral Ischemia-Reperfusion Injury by Downregulating Ferroptosis via the Nrf2/FPN Pathway in Rats.
    Biological & pharmaceutical bulletin, 2022, Volume: 45, Issue:9

    Topics: Animals; Brain Ischemia; Cation Transport Proteins; Edaravone; Ferroptosis; Glutathione; Infarction,

2022
Keap1-Nrf2/ARE Pathway-based Investigation into the Mechanism of Edaravone Dexborneol in Cerebral Infarction Model Neuroprotection.
    Cellular and molecular biology (Noisy-le-Grand, France), 2022, Sep-30, Volume: 68, Issue:9

    Topics: Animals; Brain Ischemia; Cerebral Infarction; Edaravone; Inflammation; Kelch-Like ECH-Associated Pro

2022
Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury.
    Molecular pharmaceutics, 2023, 06-05, Volume: 20, Issue:6

    Topics: Animals; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Ionic Liquids; Ischemic Str

2023
A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats.
    European journal of pharmacology, 2023, Jul-15, Volume: 951

    Topics: Animals; Brain Ischemia; Edaravone; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Strok

2023
Clinical and Pathological Benefits of Edaravone for Alzheimer's Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model.
    Journal of Alzheimer's disease : JAD, 2019, Volume: 71, Issue:1

    Topics: Alzheimer Disease; Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Male; Mice; Mice, Tra

2019
Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer's disease model mouse.
    Brain research, 2019, 11-15, Volume: 1723

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barri

2019
Effects of Edaravone on Nitric Oxide, Hydroxyl Radicals and Neuronal Nitric Oxide Synthase During Cerebral Ischemia and Reperfusion in Mice.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:3

    Topics: Animals; Brain; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavengers; Hydroxyl

2020
Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia/reperfusion injury via oxidative stress and Nrf2 pathway regulation.
    International journal of oncology, 2020, Volume: 57, Issue:2

    Topics: Animals; Brain Ischemia; CA1 Region, Hippocampal; Combined Modality Therapy; Disease Models, Animal;

2020
Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke.
    Molecular pharmaceutics, 2020, 09-08, Volume: 17, Issue:9

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Exosomes; Infarction, Middle Cerebral Ar

2020
Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2021, Volume: 41, Issue:6

    Topics: Alzheimer Disease; Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Male; Mice; Neuroprot

2021
Design, synthesis, and neuroprotective effects of novel hybrid compounds containing edaravone analogue and 3-n-butylphthalide ring-opened derivatives.
    Biochemical and biophysical research communications, 2021, 06-04, Volume: 556

    Topics: Animals; Apoptosis; Benzofurans; Brain Ischemia; Cell Line; Cell Line, Tumor; Drug Design; Edaravone

2021
ACUTE ISCHEMIC STROKE IN WOMEN: EFFICACY OF THE FREE RADICAL SCAVENGER EDARAVONE.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2021, Volume: 74, Issue:1

    Topics: Brain Ischemia; Edaravone; Female; Free Radical Scavengers; Humans; Ischemic Stroke; Prospective Stu

2021
Establishing a high throughput drug screening system for cerebral ischemia using zebrafish larvae.
    Journal of pharmacological sciences, 2021, Volume: 147, Issue:1

    Topics: Animals; Brain; Brain Ischemia; Cell Death; Disease Models, Animal; Dizocilpine Maleate; Drug Evalua

2021
Edaravone-Encapsulated Agonistic Micelles Rescue Ischemic Brain Tissue by Tuning Blood-Brain Barrier Permeability.
    Theranostics, 2017, Volume: 7, Issue:4

    Topics: Animals; Antipyrine; Blood-Brain Barrier; Brain Ischemia; Cells, Cultured; Edaravone; Endothelial Ce

2017
Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway.
    Neurological research, 2018, Volume: 40, Issue:1

    Topics: Animals; Antipyrine; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Edara

2018
Protective effects of a radical scavenger edaravone on oligodendrocyte precursor cells against oxidative stress.
    Neuroscience letters, 2018, 03-06, Volume: 668

    Topics: Animals; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Male; Mice; Mice, Inbred C5

2018
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:5

    Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Diabetes Mellitus; Disability Evaluation; Disea

2018
Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator.
    Clinical neurology and neurosurgery, 2018, Volume: 167

    Topics: Brain Ischemia; Edaravone; Female; Fibrinolytic Agents; Free Radical Scavengers; Humans; Male; Retro

2018
Edaravone, a free radical scavenger, protects neuronal cells' mitochondria from ischemia by inactivating another new critical factor of the 5-lipoxygenase pathway affecting the arachidonic acid metabolism.
    Brain research, 2018, 07-01, Volume: 1690

    Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Brain Ischemia; Caffeic Acids; Cell Death; C

2018
Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone.
    Cerebrovascular diseases (Basel, Switzerland), 2018, Volume: 45, Issue:3-4

    Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Disability Evaluation; Edaravone; Female; Free

2018
Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy.
    Stroke, 2019, Volume: 50, Issue:3

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Cohort Studies; Combined Modality Therapy; Edaravone; Endov

2019
Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke.
    Stroke, 2019, Volume: 50, Issue:7

    Topics: Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Databases, Factual; Edaravone; Humans; Japa

2019
Effects of edaravone on cerebral ischemia-reperfusion in mice through the TLR4/NF-κB/TNF-α pathway.
    Panminerva medica, 2021, Volume: 63, Issue:3

    Topics: Animals; Brain Ischemia; Edaravone; Free Radical Scavengers; Mice; Neuroprotective Agents; NF-kappa

2021
Edaravone promotes nerve function recovery after acute cerebral infarction in rats via targeting Keap1-Nrf2/ARE.
    Panminerva medica, 2021, Volume: 63, Issue:3

    Topics: Animals; Brain Ischemia; Cerebral Infarction; Edaravone; Free Radical Scavengers; Kelch-Like ECH-Ass

2021
Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Edaravone; Female; Fibrinolytic Agents;

2013
Edaravone alleviates hypoxia-acidosis/reoxygenation-induced neuronal injury by activating ERK1/2.
    Neuroscience letters, 2013, May-24, Volume: 543

    Topics: Acidosis; Animals; Antipyrine; Brain Ischemia; Brain-Derived Neurotrophic Factor; Caspase 3; Cell Hy

2013
Expression of angiotensin II and its receptors in activated microglia in experimentally induced cerebral ischemia in the adult rats.
    Molecular and cellular biochemistry, 2013, Volume: 382, Issue:1-2

    Topics: Aging; Angiotensin II; Animals; Antipyrine; Blotting, Western; Brain Ischemia; Cerebral Cortex; Edar

2013
Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:8

    Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Case-Control Studies; Chi-

2013
In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous bone marrow stromal cells (BMSCs) and edaravone.
    Neurological research, 2013, Volume: 35, Issue:10

    Topics: Animals; Antipyrine; Bone Marrow Cells; Bone Marrow Transplantation; Brain; Brain Ischemia; Disease

2013
Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice.
    Stroke, 2013, Volume: 44, Issue:12

    Topics: Animals; Antipyrine; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavengers; Mic

2013
Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.
    Journal of neuroscience research, 2014, Volume: 92, Issue:11

    Topics: Acetylglucosamine; Animals; Antipyrine; Astrocytes; Brain Ischemia; Cell Proliferation; Disease Mode

2014
The synergetic effect of edaravone and borneol in the rat model of ischemic stroke.
    European journal of pharmacology, 2014, Oct-05, Volume: 740

    Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Brain; Brain Ischemia; Camphanes; Cell Survival; Cell

2014
Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
    BMC neuroscience, 2014, Nov-22, Volume: 15

    Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Apigenin; Brain; Brain Ischemia; Cell Count; Cell Lin

2014
Compound IMM-H004, a novel coumarin derivative, protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:3

    Topics: Animals; Antipyrine; bcl-2-Associated X Protein; Brain Ischemia; CA1 Region, Hippocampal; Caspase 3;

2015
[Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury 
in rats and its underlying mechanism].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2015, Volume: 40, Issue:6

    Topics: Animals; Antipyrine; Brain Edema; Brain Ischemia; Cerebral Infarction; Edaravone; Lactates; Malondia

2015
Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2015, Volume: 31, Issue:9

    Topics: Adolescent; Antipyrine; Brain Ischemia; Child; Child, Preschool; Edaravone; Female; Free Radical Sca

2015
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model.
    Chinese medical journal, 2016, Jun-20, Volume: 129, Issue:12

    Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed

2016
Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:4

    Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Cohort Studies; Edaravone; Female; Fibrinolytic

2017
[A comparison of protective effect of propofol and edaravone pretreatment against cerebral ischemia-reperfusion injury].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2008, Volume: 20, Issue:11

    Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cell Survival; Cells, Cultured; Cerebral Cortex; Eda

2008
Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone.
    Clinical and experimental nephrology, 2009, Volume: 13, Issue:2

    Topics: Acute Kidney Injury; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Logisti

2009
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
    Stroke, 2009, Volume: 40, Issue:2

    Topics: Animals; Antipyrine; Blood Pressure; Blotting, Western; Brain Ischemia; Cells, Cultured; Cerebral He

2009
Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2009, Volume: 29, Issue:4

    Topics: Animals; Antipyrine; Basement Membrane; Brain Ischemia; Cerebral Hemorrhage; Edaravone; Free Radical

2009
Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model.
    Journal of neurotrauma, 2009, Volume: 26, Issue:9

    Topics: Animals; Antipyrine; Biomarkers; Brain Ischemia; Cerebrovascular Circulation; DNA Damage; Edaravone;

2009
Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model.
    Neuroscience, 2009, Aug-18, Volume: 162, Issue:2

    Topics: Animals; Antipyrine; Apoptosis; Axons; Blood-Brain Barrier; Brain; Brain Ischemia; Cell Proliferatio

2009
Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats.
    Brain research, 2009, Jul-07, Volume: 1279

    Topics: Amyloid beta-Protein Precursor; Animals; Antipyrine; Axons; Brain; Brain Ischemia; Edaravone; Free R

2009
Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4.
    Biochemical and biophysical research communications, 2009, Dec-25, Volume: 390, Issue:4

    Topics: Animals; Antipyrine; Aquaporin 4; Brain Edema; Brain Ischemia; Disease Models, Animal; Edaravone; Fr

2009
Repeated edaravone treatment reduces oxidative cell damage in rat brain induced by middle cerebral artery occlusion.
    Redox report : communications in free radical research, 2009, Volume: 14, Issue:6

    Topics: Animals; Antioxidants; Antipyrine; Biomarkers; Brain; Brain Ischemia; Edaravone; Free Radical Scaven

2009
[A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2010, Volume: 22, Issue:4

    Topics: Animals; Animals, Newborn; Antipyrine; Apoptosis; Brain Ischemia; Cells, Cultured; Disease Models, A

2010
A novel method for inducing focal ischemia in vitro.
    Journal of neuroscience methods, 2010, Jun-30, Volume: 190, Issue:1

    Topics: Animals; Antipyrine; Brain Ischemia; Cell Hypoxia; Cell Survival; Culture Media; Edaravone; Excitato

2010
Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains.
    Neuroscience, 2011, May-19, Volume: 182

    Topics: Animals; Antipyrine; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Edaravone; Free Ra

2011
Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Antipyrine; Brain Ischemia; Child; Disability Evaluation; Drug Therapy, Combination; Edaravone; Fema

2012
[Neuroprotective effects of combined pretreatment with edaravone and propofol on neonatal rat cerebral cortical neurons with ischemia/reperfusion injury in vitro].
    Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2012, Volume: 24, Issue:5

    Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cell Survival; Cells, Cultured; Cerebral Cortex; Eda

2012
[An improved quantitative method for evaluation of ischemic injury and neuroprotection in mouse brain slices].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2003, Volume: 32, Issue:6

    Topics: Alprostadil; Animals; Antipyrine; Brain Ischemia; Edaravone; Formazans; Male; Mice; Mice, Inbred ICR

2003
[Effects of edaravone, minocycline and ONO-1078 on oxygen/glucose deprivation-induced electrophysiological alteration in rat hippocampal slices].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Antipyrine; Brain Ischemia; Chromones; Edaravone; Evoked Potentials;

2004
Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain.
    Neurological research, 2004, Volume: 26, Issue:3

    Topics: Aldehydes; Animals; Antipyrine; Brain Ischemia; Cell Count; Deoxyadenosines; Disease Models, Animal;

2004
Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:1

    Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cells, Cultured; Edaravone; Endoplasmic Reticulum; F

2004
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
    Pharmacology, 2005, Volume: 73, Issue:1

    Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; C

2005
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 312, Issue:2

    Topics: Animals; Antipyrine; Brain; Brain Ischemia; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured

2005
Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.
    Brain research, 2004, Dec-17, Volume: 1029, Issue:2

    Topics: Animals; Antipyrine; Brain Ischemia; DNA-Binding Proteins; Edaravone; Ethidium; Free Radical Scaveng

2004
Temporal effects of edaravone, a free radical scavenger, on transient ischemia-induced neuronal dysfunction in the rat hippocampus.
    European journal of pharmacology, 2005, Apr-11, Volume: 512, Issue:2-3

    Topics: Animals; Antipyrine; Blotting, Western; Brain Ischemia; Edaravone; Fibroblast Growth Factor 2; Fluor

2005
Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats.
    European journal of pharmacology, 2005, Jun-01, Volume: 516, Issue:2

    Topics: Animals; Antipyrine; Apoptosis; bcl-2-Associated X Protein; Brain Edema; Brain Ischemia; Cerebral Co

2005
Maternal treatment with MCI-186 does not improve delayed deterioration of cellular bioenergetic state and mitochondrial activity following transient intrauterine ischemia in the fetal rat brain.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2005, Volume: 72, Issue:2

    Topics: Animals; Antipyrine; Brain; Brain Ischemia; Edaravone; Energy Metabolism; Female; Fetal Hypoxia; Fre

2005
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
    Neurological research, 2005, Volume: 27, Issue:5

    Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede

2005
Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain.
    Stroke, 2005, Volume: 36, Issue:10

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Anti-Inflammatory Agents; Antioxidants; Antipyrine;

2005
Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy.
    Stroke, 2005, Volume: 36, Issue:11

    Topics: Animals; Animals, Newborn; Antipyrine; Behavior, Animal; Brain; Brain Ischemia; Drug Administration

2005
Edaravone diminishes free radicals from circulating neutrophils in patients with ischemic brain attack.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:1

    Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Edaravone; Female; Free Radical Scavengers; Fre

2006
Reactive oxygen species generated by mitochondrial injury in human brain microvessel endothelial cells.
    Clinical hemorheology and microcirculation, 2006, Volume: 34, Issue:1-2

    Topics: Antipyrine; Brain; Brain Ischemia; Cerebrovascular Circulation; Edaravone; Endothelium, Vascular; Fr

2006
Edaravone in acute ischemic stroke.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:5

    Topics: Antipyrine; Brain Ischemia; Edaravone; Fibrinolytic Agents; Free Radical Scavengers; Tissue Plasmino

2006
Efficacy of edaravone in cardioembolic stroke.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:5

    Topics: Aged; Antipyrine; Brain Ischemia; Creatinine; Edaravone; Female; Free Radical Scavengers; Humans; In

2006
Effects of edaravone in heart of aged rats after cerebral ischemia-reperfusion injury.
    Biological & pharmaceutical bulletin, 2007, Volume: 30, Issue:3

    Topics: Aging; Animals; Antipyrine; Apoptosis; Blotting, Western; Brain Ischemia; Cell Survival; Disease Mod

2007
Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging.
    Neurologia medico-chirurgica, 2007, Volume: 47, Issue:5

    Topics: Aged; Aged, 80 and over; Antipyrine; Brain Edema; Brain Ischemia; Edaravone; Female; Free Radical Sc

2007
A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
    Brain research, 2007, Dec-05, Volume: 1183

    Topics: Animals; Antioxidants; Antipyrine; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cell Death; Do

2007
Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats.
    European journal of pharmacology, 2008, May-31, Volume: 586, Issue:1-3

    Topics: Animals; Antipyrine; Body Weight; Brain Ischemia; Cerebrovascular Circulation; Diterpenes; Dose-Resp

2008
Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 268, Issue:3

    Topics: Alloxan; Animals; Antioxidants; Antipyrine; Brain; Brain Ischemia; Edaravone; Embolization, Therapeu

1994
Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 281, Issue:2

    Topics: Animals; Antipyrine; Brain; Brain Ischemia; Cerebral Arteries; Disease Models, Animal; Edaravone; Fr

1997
[In vitro evaluation of metabolic change in forebrain ischemia model of rat using proton magnetic resonance spectroscopy].
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 1997, Volume: 72, Issue:3

    Topics: Acetates; Animals; Antipyrine; Brain; Brain Ischemia; Choline; Edaravone; Free Radical Scavengers; L

1997
Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia.
    Brain research, 1997, Jul-11, Volume: 762, Issue:1-2

    Topics: Animals; Antipyrine; Brain Ischemia; Cell Death; Edaravone; Free Radical Scavengers; Hippocampus; Hy

1997
Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion.
    General pharmacology, 1998, Volume: 30, Issue:4

    Topics: Animals; Antipyrine; Brain; Brain Ischemia; Cerebral Arteries; Constriction; Edaravone; Free Radical

1998
Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils.
    Neuroscience research, 2002, Volume: 43, Issue:1

    Topics: Animals; Anticoagulants; Antipyrine; Arginine; Body Water; Brain Edema; Brain Ischemia; Cerebral Inf

2002
Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain.
    Stroke, 1989, Volume: 20, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipyrine; Biogenic Monoamines; Brain; Brain Edema; Brain

1989